23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
26
Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS).
AstraZeneca
9
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.
Pfizer
17
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
The University of Queensland
7
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
The University of Queensland
63
The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure.
Glaxosmithkline
6
Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D
National Institute of Health Sciences
3
Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design.
National Institute of Health Sciences
20
A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors.
Glaxosmithkline
21
Novel amide and imidazole compounds as potent hematopoietic prostaglandin D
Cayman Chemical
4
Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer.
National Institute of Health Sciences
74
The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.
Glaxosmithkline
2
Characterization of crystal water molecules in a high-affinity inhibitor and hematopoietic prostaglandin D synthase complex by interaction energy studies.
Riken Center For Biosystems Dynamics Research
7
Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor.
Sanofi Us
19
NAV1.8 INHIBITOR
Wuhan Humanwell Innovative Drug Research and Development Center
1
BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity.
Upr 9023
13
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.
University of Maryland